Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Stopped early · Phase 4

Conditions studied: Schizophrenia

In brief

This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.

Key facts

Study ID

NCT00169091

Run by

Harvard Medical School (HMS and HSDM)

People needed

32

Starts

1996-03-01

Expected to finish

2003-10-01

Last updated by the study team

2015-04-07

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• RDC diagnosis of schizophrenia
• Men and women, without regard to race/ethnicity,
• Aged 18-45
• Acutely psychotic with a score of at least 3 on one of the psychotic scale items of the Brief Psychiatric Rating Scale (BPRS) (hallucinations, delusions, conceptual disorganization) and a total BPRS of > 21 (on a 0 - 6 scale);
• Require treatment with neuroleptic drugs on a clinical basis;
• The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent;
• Be within the first episode of a psychotic disorder;
• Have a history of neuroleptic treatment of < 12 weeks;
• Likely to remain in the study for 2 years.

You may not qualify if…

• Substance dependence in the last six months
• History of seizure or blood dyscrasia
• Major medical illness
• Pregnancy or Lactation

Where it is running

• Commonwealth Research Center — Jamaica Plain, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.